Description
Springer Atherosclerosis, Hypertension and Diabetes 1st Editon 2012 Softbound by Grant N. Pierce, Makoto Nagano, Peter Zahradka, Naranjan S. Dhalla
I. Atherosclerosis And Cardiovascular Disease.- 1. PPAR-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis.- 2. The Choice of an Appropriate Animal Species in the Study of Chlamydia pneumoniae as an Atherogenic Agent.- 3. Endothelial Cell Dysfunction—A Key Factor in Atherogenesis and its Reversal (Laboratory and Clinical Study).- 4. Biochemical Mechanisms of Hyperhomocysteinemia in Atherosclerosis: Role of Chemokine Expression.- 5. Oxyradicals and Hypercholesterolemic Atherosclerosis.- 6. Identification, Regulation and Function of LOX-1, A Novel Receptor for Ox-LDL.- 7. Atherosclerosis and Angiotensin II in Hypercholesterolemia and Diabetes. A Role for ATt Receptors Beyond Hypertension.- 8. Basic and Clinical Results of New Statin: Pitavastatin.- 9. Reducing Cardiovascular Risk With HMG CoA Reductase Inhibitors, Potential Contribution From Platelets.- 10. Rapamycin-Sensitive Signal Transduction Pathways and the Control of Adipogenesis.- II. Hypertension.- 11. Genetic Predisposition to Hypertension and Cardiovascular Disease.- 12. Role of Sympathetic Nervous System in Hypertension.- 13. Role of Hypothalamic Peptides in the Development of Hypertension.- 14. Myosin Light Chain Kinase in Endothelial Cell Calcium Signaling and Endothelial Functions.- 15. Sarpogrelate Inhibits Genes Involved in Vascular Neointimal Hyperplasia and Remodeling.- 16. A Nutritional Approach to Prevent High Blood Pressure.- 17. Cardiovascular and Renal Actions of Leptin.- 18. Brain Na, K-ATPase Enzymatic Activity and Cardiovascular Regulation.- 19. Development of Transdermal and Transbuccal Drug Delivery Systems for Cardioactive Drugs with Special Reference to Anti-Hypertensive Agents.- 20. Insulin Resistance and Experimental Hypertension.- III. Diabetes Mellitus.- 21. New Paradigm for Insulin Resistance: The HISS Story.- 22. Vanadium Effects in Diabetes.- 23. Dyslipoproteinemia and Fibrinolysis.- 24. Endothelins and Cardiovascular Disease in Diabetes.- 25. Usefulness of 5-HT2A Receptor Antagonists for the Treatment of Cardiovascular Complications in Diabetes.- 26. Selective Attenuation of Enhanced Angiotensin II Mediated Responses in the Streptozotocin Diabetic Rat Thoracic Aorta by Tempol.- 27. Role of Renin-Angiotensin System in Diabetic Heart Dysfunction and Changes in Phospholipase C Activity.- 28. Regulation of Cardiac Function in Diabetes.- 29. Diabetes and Cardiac Dysfunction.- 30. Mechanisms Underlying Contractile Dysfunction in Streptozotocin-Induced Type 1 and Type 2 Diabetic Cardiomyopathy.- 31. Protein Kinase C Signaling and Expression of the Diabetic Cardiac Phenotype.- 32. Oxidative Stress in Cardiovascular Complications of Diabetes.- 33. Augmented Energy Transfer in Rat Heart Mitochondria: Compensatory Response to Abnormal Household of Energy in Acute Diabetes.- 34. Ketosis, Tumor Necrosis Factor-a and Cardiovascular Disease in Type-1 Diabetic Patients.- 35. Epigenetic Alterations in Diabetic Cardiomyopathy.